[go: up one dir, main page]

WO2016018178A4 - Produit anti-nicotinique universel - Google Patents

Produit anti-nicotinique universel Download PDF

Info

Publication number
WO2016018178A4
WO2016018178A4 PCT/RU2015/000438 RU2015000438W WO2016018178A4 WO 2016018178 A4 WO2016018178 A4 WO 2016018178A4 RU 2015000438 W RU2015000438 W RU 2015000438W WO 2016018178 A4 WO2016018178 A4 WO 2016018178A4
Authority
WO
WIPO (PCT)
Prior art keywords
nicotine
agent
paragraph
complex anti
pharmaceutics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2015/000438
Other languages
English (en)
Russian (ru)
Other versions
WO2016018178A1 (fr
Inventor
Дмитрий Евгеньевич ДЕНИСОВ
Людмила Борисовна ТИМИРОВА
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2016018178A1 publication Critical patent/WO2016018178A1/fr
Publication of WO2016018178A4 publication Critical patent/WO2016018178A4/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne la pharmacie et la parapharmacie et notamment des produits pour se déshabituer du tabac. On propose un produit anti-nicotinique complexe contenant de la nicotine ou un alcaloïde de type nicotine et des acides aminés théanine 5-200 mg et tryptophane 8-50 mg dans une dose. Le produit peut être conditionnée sous forme de bonbons, gomme à mâcher, comprimés, gouttes, sirops et systèmes transdermiques.
PCT/RU2015/000438 2014-07-29 2015-07-10 Produit anti-nicotinique universel Ceased WO2016018178A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2014131493/15A RU2572720C1 (ru) 2014-07-29 2014-07-29 Комплексное антиникотиновое средство
RU2014131493 2014-07-29

Publications (2)

Publication Number Publication Date
WO2016018178A1 WO2016018178A1 (fr) 2016-02-04
WO2016018178A4 true WO2016018178A4 (fr) 2016-03-24

Family

ID=55087022

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2015/000438 Ceased WO2016018178A1 (fr) 2014-07-29 2015-07-10 Produit anti-nicotinique universel

Country Status (2)

Country Link
RU (1) RU2572720C1 (fr)
WO (1) WO2016018178A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG67408B1 (bg) 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости
CN115813011A (zh) * 2022-12-30 2023-03-21 东莞市吉纯生物技术有限公司 一种具有茶氨酸的雾化液的制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
JP3730522B2 (ja) * 2000-07-21 2006-01-05 太陽化学株式会社 喫煙欲求抑制組成物
ES2499067T3 (es) * 2005-10-13 2014-09-26 Nitto Denko Corporation Preparación transdérmica de nicotina y método de producción de la misma
KR20110063545A (ko) * 2008-09-17 2011-06-10 용린 리앙 비의존성, 담배중독-처치 및 해독 여과막대 및 담배 파이프, 및 그의 제조방법

Also Published As

Publication number Publication date
RU2572720C1 (ru) 2016-01-20
WO2016018178A1 (fr) 2016-02-04

Similar Documents

Publication Publication Date Title
WO2016064082A3 (fr) Nouveau dérivé aminoalkyle benzothiazépine et son utilisation
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
ZA201707096B (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
MY191297A (en) Oral solid formulation containing irinotecan and method of preparing the same
WO2013109388A3 (fr) Dérivés de 1,5-naphtyridine et inhibiteurs de melk les contenant
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
MX385518B (es) FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE.
WO2013169746A3 (fr) N-ethyl-4-hydroxyl-1-méthyl-5-(méthyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-n-phényl-1,2-dihydroquinoléine-3-carboxamide
WO2016018178A4 (fr) Produit anti-nicotinique universel
MX2015014958A (es) Nuevos derivados de triazolona o sales de la misma y composicion farmaceutica que comprende a la misma.
WO2014049585A3 (fr) Procédé de préparation d'étéxilate de dabigatran ou d'un sel pharmaceutiquement acceptable de cette substance
NZ630033A (en) Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride
WO2016142821A3 (fr) Compositions contenant un inhibiteur de la thrombine
WO2014167577A3 (fr) Synthèse du dabigatran
WO2016006975A3 (fr) Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation
WO2016006974A3 (fr) Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation
HK1243704A1 (zh) 用於在未接触疟疾的受试者中预防疟疾的他非诺喹的新方案
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
HK1245095A1 (zh) 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
HK1249408A1 (zh) 治疗葡萄膜黑素瘤的mdm2抑制剂
WO2016091805A3 (fr) Monopréparation de naloxone et comprimé multicouche
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
MX394413B (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma
WO2013188465A3 (fr) Compositions pharmaceutiques et méthodes de traitement d'une pharmacodépendance et de prévention à une rechute médicamenteuse

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15828306

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15828306

Country of ref document: EP

Kind code of ref document: A1